开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Marlene F Shehata and Alan Pater
Cervical cancer is one of the most common cancers in women. Human Papillomavirus (HPV) is the primary cause of cervical, anal, vulvar, vaginal and penile cancers as well as genital warts. Over 120 types of HPV have been isolated with more than 40 of these types infecting the epithelial lining of the anal and genital tracts [6]. HPV infections can be currently screened using the Pap cytology and the HPV DNA testing [7]. False positive Pap tests can greatly impact the patient’s psychological status and is currently costing over $ 244 M/year [10]. Given the huge economic burden associated with Pap cytology and DNA testing, the purpose of this editorial is to discuss the value of HPV vaccines in preventing HPV infections and hence reducing the economic burden of HPV diagnostic testing.